<DOC>
	<DOCNO>NCT02466087</DOCNO>
	<brief_summary>The objective project test hypothesis magnesium supplementation decrease depressive symptom adult . This study take place 12 consecutive week . While investigator follow volunteer full 12 week volunteer take magnesium supplement 6 consecutive week . Volunteers randomly assign start supplement week 1 week 7 . Volunteers take two supplement two time day total 248 mg elemental magnesium daily form magnesium chloride . This amount magnesium less tolerable upper limit 350 mg per day . The supplement provide . Volunteers ask maintain normal diet 12 week study . The primary outcome measure PHQ-9 questionnaire , validated measure depression . Secondary measure include GAD-7 Anxiety side effect .</brief_summary>
	<brief_title>Role Magnesium Supplementation Treatment Depression</brief_title>
	<detailed_description />
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<criteria>All adult least 18 year age A Patient Health Questionnaire9 ( PHQ9 ) score great equal 5 le 20 People currently treat depression still eligible participate treatment must stable ( change medication dose brand and/or change therapy regimen least 2 month ) . Active delirium dementia Medicinal treatment bipolar disorder , personality disorder schizophrenia , Glomerular Filtration Rate le 60 Irritable Bowel Disease Inflammatory Bowel Disease GERD Gastritis Pregnant report potential volunteer Myasthenia Gravis Planned elective surgery Currently take Long Term Antibiotics Fluoroquinolone Trientine Penicillamine Long Term Antivirals Digoxin Bisphosphonates Eltrombopag Opiods Calcium Channel Blockers Deferiprone Doxercalciferol Unable unwilling stop take MVI magnesium supplement</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>